Funding for this research was provided by:
National Heart, Lung, and Blood Institute (HL144927)
National Institute of General Medical Sciences (GM121342)
Received: 3 May 2022
Accepted: 4 October 2022
First Online: 31 October 2022
: Our study used de-identified data from the SMART-AV clinical trial, wherein the original patients gave informed consent as approved by each participating institute’s institutional review board [CitationRef removed]. All methods were performed in accordance with relevant guidelines and regulations.
: Not applicable.
: AH, DS, and WJR have filed a provisional patent application related to biomarker-based patient selection for cardiac resynchronization therapy and the remaining authors have no competing interests.